Lightnews — Scholar-powered news

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 16d

“We have a tendency to try to find a one-size-fits-all answer, and hormone therapy is one of the best examples of where one-size-fits-all answers do not work and lead to harmful decision making” @jama.com bit.ly/4mO0Qxr #medsky #womenshealth #menopause

Hormone Therapy for Menopause—A New Analysis of Old Data

This Medical News article discusses a new analysis of Women’s Health Initiative data that may help strengthen the understanding of menopausal hormone therapy’s benefits and risks for symptomatic women...

bit.ly

1 2

Reposted by Sara R. Fagerlie, PhD, CHCP

Myeloma Society @myeloma-society.bsky.social · 18d

Functional high-risk (FHR) myeloma (relapse< 18 months) is an unmet medical need in MM. Katja Weisel, MD, spoke about how patients at FHR may be identified and encouraged CAR-T consideration for FHR patients at first relapse. #IMS25

1 4

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 26d

What’s behind the rise in GI cancers among young adults?
Dr Marshall explores this in our latest #OncologyUnscripted.

🎥 Watch here: clinicalcaresolutions.net/activities/o...

#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC

1 1 6

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Sep 8

Final OS from FLAURA2 at #WCLC25:
osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC.
👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02)
👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky

#WCLC25: Four-Year Median OS with Osimertinib/Chemotherapy Combination in Advanced EGFR-Mutation Positive NSCLC

The final overall survival (OS) analysis from the FLAURA2 trial was presented during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) Pres...

www.cancercommunicator.com

2

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Sep 8

At #WCLC25 results of #FLAURA2 showed a 47.5 mo mOS w/ osimertinib+chemo in pts w/ advanced EGFRm+ NSCLC vs 37.6 with osi monotherapy. Benefit seen across subgroups. Longer chemo-free period with combo. #LCSM #LungCancer #NSCLC #oncsky #cansky

1 3

Reposted by Sara R. Fagerlie, PhD, CHCP

NEJM.org @nejm.org · Sep 7

MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k

#WCLC25 | @iaslc.bsky.social

Kaplan–Meier estimates of overall survival (assessed in an analysis of the time from randomization to death from any cause) among participants who received amivantamab–lazertinib and those who received osimertinib.

5 14

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Sep 6

📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Sep 6

Catch the latest updates from #WCLC25 — clinical data, expert insights, and practice-changing news, all in one place.
👉 Follow the curated feed here: Cancer Communicator | WCLC25

#LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky

1

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Sep 3

There are so many medical conferences held in Florida including this year's @ash.hematology.org annual meeting. Should we stop holding medical conferences in Florida? If they don't follow the evidence, why should the evidence be presented there? #medsky www.nytimes.com/2025/09/03/u...

Florida Says It Plans to End All Vaccine Mandates

www.nytimes.com

3

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Sep 3

"Independent rural hospitals are increasingly joining what are called clinically integrated networks, collaborative groups that allow them to avoid selling out to larger health systems while sharing resources to save money and improve patient care" #medsky #hospitalhealth www.npr.org/sections/sho...

How rural hospitals are banding together to survive

Independent and rural hospitals are collaborating with their neighbors to shore up their finances instead of joining larger health systems to stay afloat.

www.npr.org

1

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Sep 3

While I don't disagree with the majority of this, I think the models, even if they stay exactly as they are (which the won't), will be sufficiently disruptive to our everyday lives-once organizations figure out how to use them to save $$ (which they haven't) www.nytimes.com/2025/09/03/o... #AI

Opinion | The Fever Dream of Imminent ‘Superintelligence’ Is Finally Breaking

www.nytimes.com

3

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Sep 3

WA, OR, and CA health alliance formed recognizing the importance of independent science and medicine. It's unfathomable what has happened at one of our most revered institutions. www.nytimes.com/2025/09/03/u... #medsky #cdc

Snubbing Kennedy, States Announce Plans to Coordinate on Vaccines

www.nytimes.com

7 38

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Aug 31

"Patients initiating semaglutide or tirzepatide had a more than 40% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin...In a head-to-head comparison, tirzepatide showed no meaningful benefit over semaglutide." #medsky #obesitymedicine bit.ly/41xqRcq

Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction

This study evaluates the effectiveness and safety of semaglutide and tirzepatide in patients with cardiometabolic heart failure with preserved ejection fraction in clinical practice.

jamanetwork.com

5

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Aug 31

"Health care is exceptional among U.S. markets in that profits and value often don’t align...When quality is hard to assess, market power is sizable, and patients are vulnerable, corporatization carries the risk of increasing prices or reducing quality." #medsky www.nejm.org/doi/full/10....

The Corporatization Deal — Health Care, Investors, and the Profit Priority | NEJM

Corporatization represents a deal between medical organizations and investors and presumably benefits those entities. But the key question for society is whether it benefits patients and payers.

www.nejm.org

3

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Aug 31

At a dr appt, I was asked permission to use an AI app to take notes. I was told the app would record, write up notes, and delete the recording. Thoughts on this, Especially with otterai class actuin lawsuit? Should we be signing informed consent? #MedSky #AIinHealthcare #HealthTech #DigitalHealth

Otter Meeting Agent - AI Notetaker, Transcription, Insights

Otter AI Meeting Agent supports real-time transcription, live chat, automated summaries, insights, and action items.

otter.ai

1 1

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Aug 31

"since the widespread adoption of generative AI, early-career workers (ages 22-25) in the most AI-exposed occupations have experienced a 13 percent relative decline in employment even after controlling for firm-level shocks." digitaleconomy.stanford.edu/wp-content/u...

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Aug 19

$491 BILLION from MediCARE for an already fragile healthcare system "The CBO estimates that Medicare, the federal health insurance program for Americans over age 65, could potentially see as much as $491 billion from 2027 to 2034 if Congress does not act." #medsky

abcnews.go.com/US/wireStory...

1 2

Reposted by Sara R. Fagerlie, PhD, CHCP

Dr Noor Bari @njbbari3.bsky.social · Aug 17

Large but retrospective study.

People that get Zoster after C19 are at risk of other serious illnesses over the three year follow-up.

www.nature.com/articles/s41...

Cardiorenal outcomes after herpes zoster reactivation in COVID-19 survivors from a global TriNetX study - Scientific Reports

Scientific Reports - Cardiorenal outcomes after herpes zoster reactivation in COVID-19 survivors from a global TriNetX study

www.nature.com

3 30 100

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Aug 11

The order “ends up disrupting a decades-long and very productive partnership or collaboration between the federal government and the research institutions” by making federal agencies less reliable funders #medsky #academicsky
www.statnews.com/2025/08/08/t... via @statnews.com

Trump executive order seeks to centralize control of grantmaking under political appointees

A sweeping new executive order seeks to transform how the federal government awards billions of dollars in research grants

www.statnews.com

2 2

Reposted by Sara R. Fagerlie, PhD, CHCP

David Ho @davidho.bsky.social · Aug 7

It’s mind boggling how many additional people this administration is killing.

“I have been in this business for over 50 years on the front lines of public health…And I can say unequivocally that this was the most dangerous public health decision I have ever seen made by a government body.”

Federal mRNA funding cut is 'most dangerous public health decision' ever, expert says

Many public health experts and scientists say they are stunned by Health Secretary Robert F. Kennedy Jr’s decision to cancel nearly half a billion dollars in federal funding for future vaccine develop...

www.pbs.org

210 2.3K 5.3K

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Aug 3

Those companies want these data so badly. Highly recommend reading reading Empire of AI by @karenhao.bsky.social

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Aug 3

Alarm bells!!! "The administration is working with some of the largest American companies on the record-keeping system, including Google, Amazon, Apple and OpenAI. The Centers for Medicare and Medicaid Services will oversee the effort." #medsky #cansky
www.nytimes.com/2025/07/30/u...

Trump Announces Health Care Records System for Consumers

www.nytimes.com

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Aug 3

Alarm bells!!! "The administration is working with some of the largest American companies on the record-keeping system, including Google, Amazon, Apple and OpenAI. The Centers for Medicare and Medicaid Services will oversee the effort." #medsky #cansky
www.nytimes.com/2025/07/30/u...

Trump Announces Health Care Records System for Consumers

www.nytimes.com

1

Reposted by Sara R. Fagerlie, PhD, CHCP

Michael F. Wells @mfwells.bsky.social · Aug 1

Hundreds of millions of dollars suspended for cancer, diabetes, and Alzheimer's research (among many, many other equally important diseases and endeavors) and for what? What is the point of all of this? Help me understand how this makes our country better, stronger, and healthier in any way.

Thanh Neville, MD, MSHS @thanhneville.medsky.social · Aug 1

The massive list of suspended UCLA grants came out today: 300 NSF and 500 NIH grants. I am miraculously not on the list, but this is devastating. Science will be lost, progress will be frozen, people will lose jobs, and careers in science and medicine are being destroyed. This is not ok.

6 27 76

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Jul 18

ODAC voted against the overall benefit-risk of belantamab mafodotin combinations (BVd and BPd) not disputing the drug's efficacy, but citing toxicity and a missed opportunity to optimize dose along with inadequate enrollment of the US population. #MMSM #FDA www.youtube.com/live/CLhBI3U...

1

Reposted by Sara R. Fagerlie, PhD, CHCP

Jeremy Berg @jeremymberg.bsky.social · Jul 15

Update on funding curves and late non-competitive renewals.

First, funding curves for new and competitive renewals.

1/n

Graph showing NIH funding for new and competitive renewal grants for fiscal year 2025 compared to fiscal year 2024. The fiscal year 2025 curve is substantially below the fiscal year 2024 curve.

4 51 91